GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (FRA:A71) » Definitions » Shiller PE Ratio

Ascendis Pharma A/S (FRA:A71) Shiller PE Ratio : (As of May. 19, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma A/S Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Shiller PE Ratio Historical Data

The historical data trend for Ascendis Pharma A/S's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Shiller PE Ratio Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascendis Pharma A/S's Shiller PE Ratio

For the Biotechnology subindustry, Ascendis Pharma A/S's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Shiller PE Ratio falls into.



Ascendis Pharma A/S Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ascendis Pharma A/S's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ascendis Pharma A/S's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.3/118.4000*118.4000
=-2.300

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.198 99.700 -0.235
201409 -0.117 99.700 -0.139
201412 -0.297 99.400 -0.354
201503 0.060 100.200 0.071
201506 -0.630 100.300 -0.744
201509 -0.300 100.200 -0.354
201512 -0.490 99.800 -0.581
201603 -0.820 100.200 -0.969
201606 -0.530 100.600 -0.624
201609 -0.720 100.200 -0.851
201612 -0.510 100.300 -0.602
201703 -0.780 101.200 -0.913
201706 -0.940 101.200 -1.100
201709 -1.040 101.800 -1.210
201712 -0.920 101.300 -1.075
201803 -1.070 101.700 -1.246
201806 -0.550 102.300 -0.637
201809 -0.810 102.400 -0.937
201812 -0.760 102.100 -0.881
201903 -1.240 102.900 -1.427
201906 -1.250 102.900 -1.438
201909 -0.530 102.900 -0.610
201912 -1.700 102.900 -1.956
202003 -1.320 103.300 -1.513
202006 -1.970 103.200 -2.260
202009 -2.310 103.500 -2.643
202012 -2.640 103.400 -3.023
202103 -1.170 104.300 -1.328
202106 -2.500 105.000 -2.819
202109 -1.470 105.800 -1.645
202112 -1.870 106.600 -2.077
202203 -2.210 109.900 -2.381
202206 -1.460 113.600 -1.522
202209 -3.030 116.400 -3.082
202212 -3.700 115.900 -3.780
202303 -1.980 117.300 -1.999
202306 -2.160 116.400 -2.197
202309 -2.880 117.400 -2.905
202312 -1.540 116.700 -1.562
202403 -2.300 118.400 -2.300

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (FRA:A71) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ascendis Pharma A/S Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (FRA:A71) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (FRA:A71) Headlines

No Headlines